Although EGFR-TKIs (tyrosine kinase inhibitors) have dramatically improved the clinical outcomes of non-small cell lung cancer (NSCLC) patients harboring EGFR-sensitive mutations (exon 19 deletion or exon 21 p.L858R), the mechanism of the poor efficacy of targeted therapy remains unclear. Here, EGFR is linked to non-small cell lung carcinoma.